tert-butyl 3-((pyridin-3-yloxy)methyl)piperazine-1-carboxylate | 960535-17-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 3-((pyridin-3-yloxy)methyl)piperazine-1-carboxylate
• 英文别名: Tert-butyl 3-(pyridin-3-yloxymethyl)piperazine-1-carboxylate
• CAS: 960535-17-5
• 化学式: C₁₅H₂₃N₃O₃
• 分子量: 293.366
• InChiKey: RCVANPPRWRQKCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  63.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-((pyridin-3-yloxy)methyl)piperazine-1-carboxylate 在 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 5.0h， 生成 4-(tert-butyl) 1-(4-chlorophenyl) 2-((pyridin-3-yloxy)methyl)piperazine-1,4-dicarboxylate
  参考文献：
  名称：

  Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as α7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders

  摘要：

  Herein we report the design, synthesis, and structure activity relationships for a new class of alpha 7 nicotinic acetylcholine receptor (nAChR) modulators based on the 2-((pyridin-3-yloxy)methyl)piperazine scaffold. The oxazolo[4,5-b]pyridine, (R)-18, and 4-methoxyphenylurea, (R)-47, were identified as potent and selective modulators of the alpha 7 nAChR with favorable in vitro safety profiles and good oral bioavailability in mouse. Both compounds were shown to significantly inhibit cellular infiltration in a murine model of allergic lung inflammation. Despite the structural and in vivo functional similarities in the compounds, only (R)-18 was shown to be an agonist. Compound (R)-47 demonstrated silent agonist activity. These data support the hypothesis that the anti-inflammatory activity of the alpha 7 nAChR is mediated by a signal transduction pathway that is independent of ion current.

  DOI：

  10.1021/jm5004599
• 作为产物：
  描述：

  1,4-双(N-Boc)哌嗪-2-甲酸 在 硼烷四氢呋喃络合物 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 123.5h， 生成 tert-butyl 3-((pyridin-3-yloxy)methyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as α7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders

  摘要：

  Herein we report the design, synthesis, and structure activity relationships for a new class of alpha 7 nicotinic acetylcholine receptor (nAChR) modulators based on the 2-((pyridin-3-yloxy)methyl)piperazine scaffold. The oxazolo[4,5-b]pyridine, (R)-18, and 4-methoxyphenylurea, (R)-47, were identified as potent and selective modulators of the alpha 7 nAChR with favorable in vitro safety profiles and good oral bioavailability in mouse. Both compounds were shown to significantly inhibit cellular infiltration in a murine model of allergic lung inflammation. Despite the structural and in vivo functional similarities in the compounds, only (R)-18 was shown to be an agonist. Compound (R)-47 demonstrated silent agonist activity. These data support the hypothesis that the anti-inflammatory activity of the alpha 7 nAChR is mediated by a signal transduction pathway that is independent of ion current.

  DOI：

  10.1021/jm5004599

文献信息

• Novel piperazines, pharmaceutical compositions and methods of use thereof
  申请人：Clark B. Roger

  公开号：US20080051415A1

  公开（公告）日：2008-02-28

  Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

  本发明涉及一种新的哌嗪衍生物，其作为α7 nAChR的激动剂。同时还揭示了制药组合物，治疗炎症疾病的方法，治疗中枢神经系统疾病的方法，抑制哺乳动物细胞细胞因子释放的方法以及制备新化合物的方法。
• Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof
  申请人：Clark Roger B.

  公开号：US20120071652A1

  公开（公告）日：2012-03-22

  Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

  本发明涉及新型哌嗪衍生物，其作为α7 nAChR的激动剂。本发明还涉及制药组合物、治疗炎症性疾病的方法、治疗中枢神经系统疾病的方法、抑制哺乳动物细胞细胞因子释放的方法以及制备新型化合物的方法。
• WO2007/146066
  申请人：——

  公开号：——

  公开（公告）日：——
• NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Cornerstone Therapeutics Inc.

  公开号：EP2044038A2

  公开（公告）日：2009-04-08
• US20140343059A1
  申请人：——

  公开号：US20140343059A1

  公开（公告）日：2014-11-20